Saltigo signs agreement with Daiichi Sankyo

Published: 8-Jul-2013
Manufacturing

Lanxess subsidiary provides contract manufacturing services for Japanese pharmaceutical company


German custom manufacturing specialist Saltigo is continuing the development of its pharmaceutical business portfolio by signing an agreement with Daiichi Sankyo for the provision of contract manufacturing services.

These services are associated with the preparation for commercialisation of one of Daiichi Sankyo’s novel drug pipeline projects.

A signing ceremony took place in Tokyo in the presence of Katsumi Fujimoto, Executive Vice President, Pharmaceutical Technology Division of Daiichi Sankyo, and Wolfgang Schmitz, Managing Director of Saltigo.

Schmitz said: ‘Daiichi Sankyo is one of the largest pharma players in the second-largest pharma market in the world and decided to work with a globally recognised CMO-partner such as our company. So, it is a great honour for Saltigo to enter into this agreement.’

No financial or further details have been revealed.

  • Companies:
  • Saltigo
  • Daiichi Sankyo
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Looking ahead to a challenging year

Read more
Asia is emerging as a rival to the US as a leading source of drug discovery and high end innovation. Both clinical trials activity and investments by drug majors are set to expand in Asia, with India and China leading the charge. But the Indian, Chinese and Philippino governments are proposing to increase price controls on medicines, and lax intellectual property laws across the region could hinder growth.

Trending Articles

  1. TekniPlex Healthcare to showcase expanded capacity and sustainability solutions at Pharmapack Company highlights EU-based advancements in injection blow molding, multilayer blown films, and sustainable blister packaging
  2. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be complicated. Here, the tablet experts Natoli explain how to develop tabletability, compactibility, and compressibility profiles
  5. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Looking ahead to a challenging year

Asia is emerging as a rival to the US as a leading source of drug discovery and high end innovation. Both clinical trials activity and investments by drug majors are set to expand in Asia, with India and China leading the charge. But the Indian, Chinese and Philippino governments are proposing to increase price controls on medicines, and lax intellectual property laws across the region could hinder growth.
Manufacturing

Daiichi Sankyo acquires first US-based packaging facility

Strengthens global supply chain capabilities
Manufacturing

Saltigo agrees cooperation with RCA

Extends synthesis services
Manufacturing

Saltigo supports customers in the early phases of active ingredient development

<p>Serving innovative pharmaceutical companies - expertly and flexibly </p><p>Satisfied customers always come back</p>
Media

Saltigo nearly doubles capacity for active ingredient precursor

<p>Saltigo, a wholly owned subsidiary of German speciality chemicals group Lanxess, has nearly doubled capacity for an active ingredient precursor for a major pharmaceutical manufacturer without needing to halt or interrupt the production process. </p>
Manufacturing

Saltigo to showcase portfolio at Chemspec Europe

<p>Saltigo, a global service provider for custom synthesis and custom manufacturing, is set to showcase its product portfolio at Chemspec Europe 2008 next week.</p>
Manufacturing

Saltigo establishes US production and development services for pharmacompanies

<p>LANXESS Corporation has established a new site in Redmond, Washington, to serve the growing pharmaceutical business line of its affiliate, Saltigo GmbH (a subsidiary of LANXESS Deutschland GmbH). </p>
Subscribe now